# GlucoShield — Project Progress & Milestone Log
**Project Title:** GlucoShield — Multi-Modal AI & Mechanistic Digital Twin Diabetes Companion  
**Current Date:** 2026-08-28  
**Current Phase:** **PHASE 6 COMPLETED (Research-Grade Evaluation & Statistical Validation)**  
**Overall Completion:** **100% of Planned Core ML/Physiology/Decision Engine & Research Validation Pipeline**  

---

## Completed Phases & Milestone Tracker

| Phase / Milestone | Status | Key Artifacts & Checkpoints | Key Metrics / Verdict |
|---|:---:|---|---|
| **Phase 0: Architecture & Dataset Lock** | **COMPLETED** | `data/final/` ($N=28,447$ seqs, 112 patients)<br>`reports/DAY1_DATASET_LOCK_REPORT.md`<br>`DATASET.md` | Patient-wise disjoint splits ($78$ Train / $17$ Val / $17$ Test). Zero leakage. Zero NaNs. |
| **Phase 1: Baseline Benchmarking** | **COMPLETED** | `models/baseline_ridge.joblib`<br>`reports/DAY2_BASELINE_REPORT.md` | Ridge Test MAE: $25.37\text{ mg/dL}$, RMSE: $35.80\text{ mg/dL}$, Clarke A+B: $93.31\%$. |
| **Phase 2: Neural Forecaster V1** | **COMPLETED** | `models/glucoshield_neural_best.pt`<br>`reports/DAY3_NEURAL_FORECASTER_REPORT.md` | Single-layer GRU (hidden=128), Test MAE: $24.45\text{ mg/dL}$, RMSE: $34.90\text{ mg/dL}$, Clarke A+B: $95.28\%$. |
| **Phase 3: Digital Twin & 20-Point Tests** | **COMPLETED** | `physiology/`<br>`reports/DAY4_PHYSIOLOGY_TEST_REPORT.md` | 6-compartment ODE system, differentiable RK4. **20 / 20 Unit Tests Passed ($100\%$)**. |
| **Phase 4: Standalone ODE Validation** | **COMPLETED** | `results/digital_twin/standalone_ode_validation_results.json` | Population ODE: $49.74\text{ mg/dL}$<br>Prior ODE: $46.58\text{ mg/dL}$<br>Calibrated ODE: $46.68\text{ mg/dL}$. |
| **Phase 5: Hybrid Fusion & Multi-Seed Lock** | **COMPLETED** | `models/glucoshield_hybrid_best.pt`<br>`reports/DAY4_DIGITAL_TWIN_VALIDATION_SELECTION.md` | Multi-seed Val RMSE: $30.98 \pm 0.04\text{ mg/dL}$. Winner Seed 7 ($30.93\text{ mg/dL}$). |
| **Phase 6: Single Untouched Test Evaluation** | **COMPLETED** | `results/digital_twin/preds_hybrid_test.npy`<br>`reports/DAY4_FINAL_DIGITAL_TWIN_REPORT.md` | **Hybrid Test MAE: $24.14\text{ mg/dL}$, RMSE: $34.77\text{ mg/dL}$, Clarke A+B: $95.36\%$** (Beats Ridge & Neural V1). |
| **Phase 7: Counterfactual Case Studies** | **COMPLETED** | `results/digital_twin/digital_twin_experiment_summary.json` | 6 clinical scenarios verified (Meal dose/timing, Bolus dose/timing, Rescue carbs, Hyper correction). |
| **Phase 8: Uncertainty & Decision Engine** | **COMPLETED** | `decision_engine/`<br>`reports/DAY5_UNCERTAINTY_DECISION_ENGINE_REPORT.md` | 80%/95% Prediction intervals, Clinical Risk Tiering (`CRITICAL`/`WARNING`/`NORMAL`), **5 / 5 Tests Passed**. |
| **Phase 9: Research-Grade Statistical Validation** | **COMPLETED** | `evaluation/phase6/`<br>`reports/PHASE6_FINAL_RESEARCH_EVALUATION.md`<br>`REPRODUCIBILITY.md` | **Per-patient tests ($N=17$), 10k bootstrap CIs, Wilcoxon MAE $p=0.0039$, 6 figures, 7/7 Phase 6 Tests Passed**. |

---
*Status verified and recorded.*
